Fly News Breaks for March 3, 2015
OREX
Mar 3, 2015 | 10:47 EDT
Leerink says Orexigen this morning unexpectedly disclosed the data from the 25% interim analysis of the LIGHT Contrave cardiovascular study when announcing a method of treatment patent was issued. The firm notes the data show a statistically significant Contrave benefit in the intent-to-treat population on MACE, myocardial infarction, stroke, and cardiovascular death. Leerink believes the results "present meaningful upside to expectations" and could have a positive impact on the Contrave launch if they are included on the drug's labels. It reiterates an Outperform rating on Orexigen.
News For OREX From the Last 2 Days
There are no results for your query OREX